Molecule News and Research

RSS

Pacific Biosciences selects Camstar Manufacturing enterprise software to deliver innovative products

Camstar Systems, Inc. announced today that Pacific Biosciences, a leader in the development of a transformative Single Molecule Real Time (SMRT™) DNA sequencing platform, has selected the Camstar Manufacturing™ enterprise software platform to enable its critical transition from product development to high-volume production, and to ensure consistent top product quality.

12 Nov 2009

Researchers identify new mechanism to create lasting memories; findings may yield potential treatment for memory impairments

Researchers at the Swedish medical university Karolinska Institutet have discovered a mechanism that controls the brain's ability to create lasting memories. In experiments on genetically manipulated mice, they were able to switch on and off the animals' ability to form lasting memories by adding a substance to their drinking water. The findings, which are published in the scientific journal PNAS, are of potential significance to the future treatment of Alzheimer's and stroke.

11 Nov 2009

NIDA supports new drug detection research

Every time a person snorts cocaine, it doesn't just go to his or her head: It also provokes a response in the immune system, creating special biomolecules that may serve as a permanent record of each exposure.

11 Nov 2009

MicroDose Therapeutx acquires potential compounds for treatment of respiratory syncytial virus

MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has acquired a portfolio of compounds for the potential treatment of respiratory syncytial virus (RSV) from ViroPharma Incorporated (Exton, PA). The lead investigational compound in the portfolio is an inhalable small molecule fusion inhibitor, now called MDT-637.

10 Nov 2009

New imagining technique may yield better antiviral and anti-cancer drugs

A recently devised method of imaging the chemical communication and warfare between microorganisms could lead to new antibiotics, antifungal, antiviral and anti-cancer drugs, said a Texas AgriLife Research scientist.

10 Nov 2009

Yo-yo dieting and sugar-bingeing can lead to anxiety and withdrawal symptoms

In research that sheds light on the perils of yo-yo dieting and repeated bouts of sugar-bingeing, researchers from The Scripps Research Institute have shown in animal models that cycling between periods of eating sweet and regular-tasting food can activate the brain's stress system and generate overeating, anxiety, and withdrawal-like symptoms.

10 Nov 2009

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Emisphere Technologies, Inc. today announced financial and operational results for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

Caliper Life Sciences announces financial results for third quarter ended September 30, 2009

Caliper Life Sciences, Inc. today reported results for its third quarter ended September 30, 2009. GAAP revenues increased by 4% to $32.2 million, from non-GAAP revenues of $31.0 million in the same period of 2008, which represents GAAP revenue of $34.0 million in the third quarter of 2008 reduced by $3.0 million for the impact of divested product lines.

9 Nov 2009

Researchers develop tools to visualize how different cell populations of cells communicate

Using imaging mass spectrometry, researchers at the University of California, San Diego have developed tools that will enable scientists to visualize how different cell populations of cells communicate. Their study shows how bacteria talk to one another - an understanding that may lead to new therapeutic discoveries for diseases ranging from cancer to diabetes and allergies.

9 Nov 2009

Researchers discover a fungal protein that causes disease in plants and animals

Researchers at the Virginia Bioinformatics Institute (VBI) at Virginia Tech and Montana State University have discovered a fungal protein that plays a key role in causing disease in plants and animals and which also shields the pathogen from oxidative stress.

7 Nov 2009

Researchers find compound that reverses type 1 myotonic dystrophy

A compound already used to treat pneumonia could become a new therapy for an inherited muscular wasting disease, according to researchers at the University of Oregon and the University of Rochester School of Medicine and Dentistry in New York.

7 Nov 2009

Graceway Pharmaceuticals acquires global rights to Gilead Sciences' GS 9191 anti-proliferative agent

Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, today announced that the company has acquired from Gilead Sciences, Inc. the worldwide license, including related regulatory filings and intellectual properties, to Gilead’s investigational molecule, GS 9191, for topical use. GS 9191 is an anti-proliferative agent that works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.

7 Nov 2009

New findings may lead to novel therapeutic approaches for HIV and prostate cancer

New Haven, Conn.-Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases.

6 Nov 2009

Boosting NAD+ after spinal cord injury may prevent permanent nerve death

Substances naturally produced by the human body may one day help prevent paralysis following a spinal cord injury, according to researchers at Weill Cornell Medical College. A recent $2.5 million grant from the New York State Spinal Cord Injury Research Board will fund their research investigating this possibility.

6 Nov 2009

Varian launches its 325-MS triple-quadrupole liquid chromatograph/mass spectrometer

Varian, Inc. announced today the release of the 325-MS triple-quadrupole LC/MS (liquid chromatograph/mass spectrometer) for the efficient detection and identification of chemical compounds in high-throughput laboratories performing environmental, food safety, and toxicology analyses.

6 Nov 2009

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

ArQule, Inc. today reported its results of operations for the fiscal quarter and nine months ended September 30, 2009.

5 Nov 2009

NIST researchers to develop a certified reference material to assess C-reactive protein

Searching for a needle in a haystack may seem futile, but it's worth it if the needle is a hard-to-detect protein that may identify a person at high risk of a heart attack circulating within a haystack of human serum (liquid component of blood).

5 Nov 2009

Tetracycline-like compound raises hope for treatment of spinal muscular atrophy

A chemical cousin of the common antibiotic tetracycline might be useful in treating spinal muscular atrophy (SMA), a currently incurable disease that is the leading genetic cause of death in infants. This is the finding of a research collaboration involving Adrian Krainer, Ph.D., of Cold Spring Harbor Laboratory (CSHL) and scientists from Paratek Pharmaceuticals and Rosalind Franklin University of Medicine and Science.

5 Nov 2009

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

Peregrine Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,611,704, which includes broad claims covering anti-viral uses of phosphatidylserine (PS)-targeting antibodies including Peregrine's lead clinical compound, bavituximab. PS is a unique marker exposed on the surface of virally infected cells that can be targeted to treat a broad spectrum of virus infections.

5 Nov 2009

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter and nine-month period ended September 30, 2009. Celldex reported a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009 compared to a net loss of $7.7 million, or $0.49 per share, for the third quarter of 2008.

4 Nov 2009

Molecule News and Research

Pacific Biosciences selects Camstar Manufacturing enterprise software to deliver innovative products

Researchers identify new mechanism to create lasting memories; findings may yield potential treatment for memory impairments

NIDA supports new drug detection research

MicroDose Therapeutx acquires potential compounds for treatment of respiratory syncytial virus

New imagining technique may yield better antiviral and anti-cancer drugs

Yo-yo dieting and sugar-bingeing can lead to anxiety and withdrawal symptoms

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Caliper Life Sciences announces financial results for third quarter ended September 30, 2009

Researchers develop tools to visualize how different cell populations of cells communicate

Researchers discover a fungal protein that causes disease in plants and animals

Researchers find compound that reverses type 1 myotonic dystrophy

Graceway Pharmaceuticals acquires global rights to Gilead Sciences' GS 9191 anti-proliferative agent

New findings may lead to novel therapeutic approaches for HIV and prostate cancer

Boosting NAD+ after spinal cord injury may prevent permanent nerve death

Varian launches its 325-MS triple-quadrupole liquid chromatograph/mass spectrometer

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

NIST researchers to develop a certified reference material to assess C-reactive protein

Tetracycline-like compound raises hope for treatment of spinal muscular atrophy

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News